GlassScriptPhysician profile
Deborah Khalife
NPI 1063855237
$3,624.06
in general payments reported to CMS, 2019-2025
22 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $640 · 2022: $715 · 2023: $912 · 2024: $775 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $634.07 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $526.39 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $479.54 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $323.43 | 2021-2024 | |
| Lilly USA, LLC | $226.53 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.75 | 2022-2025 | Jardiance |
| Amgen INC. | $160.18 | 2021-2025 | Otezla, Repatha, Otezla |
| Esperion Therapeutics, INC. | $148.00 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $135.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $114.90 | 2024-2025 | |
| Shield Therapeutics INC | $96.91 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.92 | 2021-2025 | Xifaxan |
| Amarin Pharma, INC. | $73.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $70.99 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.50 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $62.59 | 2021-2024 | Spravato |
| Phathom Pharmaceuticals, INC. | $61.29 | 2024-2025 | Voquezna |
| Dexcom, INC. | $51.46 | 2022-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $29.52 | 2021 | |
| Merck Sharp & Dohme LLC | $25.68 | 2021-2022 | |
| Radius Health, INC. | $23.46 | 2025 | Tymlos |
| Avanir Pharmaceuticals, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Khalife listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.